Triptorelin

The most established use of triptorelin is in central precocious puberty (CPP), where children begin pubertal development years earlier than typical. A 2024 Phase 3 trial of the 6-month, 22.5 mg depot formulation in children with CPP found that 100% of participants achieved LH suppression at month 6, and 98.5% maintained suppression at month 12 (1). Sex hormones returned to prepubertal levels in all patients, breast development stabilized or regressed in 98% of girls, and growth velocity slowed appropriately — from roughly 9.8 cm/year at baseline to 5.2 cm/year at month 12. Bone age progression also slowed relative to chronological age, which is the key marker for preserving adult height potential.

A broader review of the depot formulations — 3.75 mg monthly, 11.25 mg quarterly, and 22.5 mg semi-annually — found that all three reliably suppress the pituitary-gonadal axis, with the longer-acting versions producing comparable end results to the monthly dose (2). Long-term follow-up has not identified adverse effects on later reproductive function, though researchers continue to study whether CPP itself, or its treatment, influences risks like hyperandrogenism in adulthood.

In premenopausal women with endocrine-responsive early breast cancer, triptorelin is used to induce ovarian function suppression (OFS) — temporarily shutting down estrogen production from the ovaries so that hormone-blocking therapies can work more completely. The landmark SOFT and TEXT trials, summarized in a comprehensive review, established that adding triptorelin-induced OFS to tamoxifen improved disease control and overall survival in higher-risk patients who had previously received chemotherapy and remained premenopausal afterward (3).

The combination of OFS plus exemestane (an aromatase inhibitor) produced even stronger disease control benefits than OFS plus tamoxifen, though with a different side effect profile. OFS plus tamoxifen tended toward more vasomotor symptoms and thromboembolic events, while OFS plus exemestane was associated with more musculoskeletal symptoms, reduced libido, and bone density loss. Both combinations are now considered valid adjuvant strategies for premenopausal patients at sufficient recurrence risk to have warranted chemotherapy, with the choice individualized to the patient's risk profile and tolerability priorities.

Triptorelin plays a different role in fertility medicine, where it's used to control the timing of ovulation during in vitro fertilization and related procedures. The peptide's initial flare effect can trigger a controlled LH surge, while sustained dosing prevents premature ovulation during ovarian stimulation — both useful for synchronizing egg retrieval.

A 2023 study explored a novel delivery approach: silk fibroin-based microneedle patches loaded with triptorelin nanoparticles, designed to replace repeated subcutaneous injections during ART cycles (4). The microneedle system achieved roughly 65% transdermal release, prolonged the drug's half-life, and increased bioavailability compared with conventional injection. Plasma LH and estradiol showed the expected surge-then-suppression pattern, suggesting the patch could deliver the same hormonal effect with less injection burden — a quality-of-life consideration that matters during the demanding schedule of fertility treatment. The work is preclinical, but it illustrates the active interest in making triptorelin easier to use without changing what it does pharmacologically.

Triptorelin is also used as a puberty blocker for transgender and gender-diverse adolescents experiencing gender dysphoria, allowing time to explore gender identity before irreversible pubertal changes occur. A 2025 comparative review examined its use in this context across international settings, summarizing both the documented benefits — reduction of psychological distress in many patients — and the recognized side effects, which include slowed growth, increased BMI, and concerns about bone density during the suppression period (5).

The review highlighted significant variation in how different countries structure access, supervision, and psychological support around this use. In Italy, a parliamentary inquiry into the adequacy of psychological support led to suspension of therapy in some centers. The authors call for clearer multidisciplinary guidelines and better-resourced clinical frameworks rather than questioning the underlying pharmacology, which is the same well-characterized GnRH suppression used in CPP.

Reported side effects of triptorelin reflect its hormonal mechanism. In children with central precocious puberty, about 20% experienced drug-related adverse events in the most recent Phase 3 trial, none rated grade 3 or higher (1). Across long-term use in CPP, slowed growth velocity, increased BMI, and effects on bone density during suppression have been documented (2, 5). In adult oncology use, induced menopause produces vasomotor symptoms, mood changes, reduced libido, and — particularly when combined with aromatase inhibitors — bone density loss and musculoskeletal symptoms (3). Local injection site reactions are common across all uses. Rare but serious adverse events have been described, which is why depot use in children is generally restricted to specialist endocrinology centers. The body of triptorelin evidence includes substantial human clinical trial data across multiple indications, supplemented by ongoing preclinical work on newer delivery formulations.